Allergan Defends Bylaws Amid Effort to Ward Off Valeant

Allergan is defending corporate bylaws that have emerged as a flash point in its effort to ward off a $53 billion hostile takeover by Valeant Pharmaceuticals.



from WSJ.com: US Business http://ift.tt/1qM09aC

via IFTTT